Soligenix Current Ratio 2010-2022 | SNGX

Soligenix current ratio from 2010 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Soligenix Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $0.02B $0.01B 1.81
2022-06-30 $0.02B $0.01B 2.36
2022-03-31 $0.02B $0.01B 3.25
2021-12-31 $0.03B $0.01B 4.22
2021-09-30 $0.03B $0.01B 6.14
2021-06-30 $0.03B $0.00B 7.12
2021-03-31 $0.03B $0.00B 7.27
2020-12-31 $0.02B $0.01B 3.20
2020-09-30 $0.01B $0.01B 2.30
2020-06-30 $0.01B $0.01B 2.00
2020-03-31 $0.01B $0.01B 1.51
2019-12-31 $0.01B $0.01B 1.19
2019-09-30 $0.01B $0.01B 1.42
2019-06-30 $0.01B $0.01B 1.60
2019-03-31 $0.01B $0.00B 2.20
2018-12-31 $0.01B $0.00B 2.46
2018-09-30 $0.01B $0.00B 3.27
2018-06-30 $0.01B $0.00B 1.67
2018-03-31 $0.01B $0.00B 2.16
2017-12-31 $0.01B $0.00B 2.92
2017-09-30 $0.01B $0.00B 2.13
2017-06-30 $0.01B $0.00B 2.11
2017-03-31 $0.01B $0.00B 3.19
2016-12-31 $0.01B $0.00B 3.52
2016-09-30 $0.01B $0.01B 1.36
2016-06-30 $0.01B $0.01B 0.97
2016-03-31 $0.01B $0.01B 0.81
2015-12-31 $0.01B $0.01B 0.97
2015-09-30 $0.01B $0.01B 0.89
2015-06-30 $0.01B $0.01B 0.56
2015-03-31 $0.01B $0.01B 0.71
2014-12-31 $0.01B $0.01B 0.91
2014-09-30 $0.01B $0.01B 0.55
2014-06-30 $0.01B $0.01B 0.52
2014-03-31 $0.01B $0.01B 0.58
2013-12-31 $0.01B $0.01B 0.76
2013-09-30 $0.01B $0.01B 0.62
2013-06-30 $0.01B $0.01B 1.25
2013-03-31 $0.00B $0.00B 2.05
2012-12-31 $0.00B $0.00B 3.32
2012-09-30 $0.00B $0.00B 3.94
2012-06-30 $0.01B $0.00B 3.81
2012-03-31 $0.01B $0.00B 4.30
2011-12-31 $0.01B $0.00B 4.98
2011-09-30 $0.01B $0.00B 5.43
2011-06-30 $0.01B $0.00B 3.22
2011-03-31 $0.01B $0.00B 4.28
2010-12-31 $0.01B $0.00B 4.19
2010-09-30 $0.01B $0.00B 6.19
2010-06-30 $0.01B $0.00B 6.13
2010-03-31 $0.01B $0.00B 6.22
2009-12-31 $0.01B $0.00B 6.53
2009-09-30 $0.01B $0.00B 4.97
2009-06-30 $0.01B $0.00B 4.02
2009-03-31 $0.01B $0.00B 5.66
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.020B $0.001B
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $155.188B 9.47
GSK (GSK) United Kingdom $72.345B 9.01
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.333B 19.34
Ginkgo Bioworks Holdings (DNA) United States $3.395B 0.00
Myovant Sciences (MYOV) United Kingdom $2.604B 0.00
Arcus Biosciences (RCUS) United States $1.672B 25.10
Biohaven (BHVN) United States $1.264B 0.00
Emergent Biosolutions (EBS) United States $0.655B 5.15
ADC Therapeutics SA (ADCT) Switzerland $0.363B 0.00
Ambrx Biopharma (AMAM) United States $0.073B 0.00
Enzo Biochem (ENZ) United States $0.073B 0.00
Gelesis Holdings (GLS) United States $0.027B 0.00
SQZ Biotechnologies (SQZ) United States $0.025B 0.00